The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2018 | Resistance mechanisms in CLL
Relapsed chronic lymphocytic leukemia (CLL) patients exhibit unforeseen aberrations in ribosomal genes, says Richard Rosenquist, MD, PhD, of the Karolinska University Hospital, Solna, Sweden. Prof. Rosenquist further expresses his hope of understanding resistance mechanisms in CLL using next-generation sequencing, at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
